One of the most exciting promises of cell and gene therapies is their potential to tailor treatment to individuals and thus improve the lives of those with rare diseases. However, developing these therapeutics blur the traditional line between treatment and research and therefore invite a number of important ethical questions. This panel will ask: How should we think about the development of these novel medical interventions—are they research or treatment? How should the development of such individual therapeutics be regulated? How can we work towards equitable access to these exciting new interventions?
P A N E L I S T S :
Alison Bateman-House, MPH, PHD Assistant Professor of Population Health, NYU Grossman School of Medicine
Allison Bradbury, MS, PhD Assistant Professor of Pediatrics, OSU & PI in the Center for Gene Therapy, Abigail Wexner Research Institute
